¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23
±³À°ÀÏÀÚ : 2023-09-23

±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°­´ç

±³À°ÁÖÁ¦ : 2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸¸¼º°ñ¼ö¼º¹éÇ÷º´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kamslor.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í Àü¹®ÀÇ 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 09:30~10:05 Third-line treatment for CML(chronic myeloid leukemia) ÇÑÀçÁØ(°æÈñÀÇ´ë)

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 10:05~10:40 Treatment in advanced phase (AP/BC) of CML(chronic myeloid leukemia) ±è°æÇÏ(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:00~11:15 ASTER-P ¹Ú¼º¿ì(°æ»óÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:15~11:30 ASTER-A ¾öÁöÀº(ÇѾçÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:30~11:45 NGS( next generation sequencing) for ABL1 mutation ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 11:45~12:00 HBV(hepatitis B virus) prophylaxis in TKI-treated CML(chronic myeloid leukemia) ÀÌÀ¯Áø(¿ï»êÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:00~13:15 Ponatinib dose optimization ÀÌÁ¤¿Á(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:15~13:30 Dasatinib dose optimization ±è»ó¾Æ(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:30~13:45 Imatinib as 1st line therapy in very elderly CML(chronic myeloid leukemia)) patients Á¶ÁøÇö(ÀÎÇÏÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 13:45~14:00 Immune effect on TFR(total fertility rate ) ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 14:00~14:15 Nilotinib dose optimization ¹ÚÇö°æ(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 09¿ù 23ÀÏ ÁöÇÏ ´ë°­´ç 14:15~14:30 Asciminib as salvage therapy in real-world CML(chronic myeloid leukemia))practice ÃÖÀºÁö(¿ï»êÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼ö¼º¹éÇ÷¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-09-23""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °ñ´Ù°øÁõ Áø´Ü ¹× Ä¡·á A to Z : 2023-09-23
´ÙÀ½±Û ´ëÇѵΰæºÎÁ¾¾çÇÐȸ 2023³â Á¦ 4ȸ µÎ°æºÎ ¿¬±¸Æ÷·³ : 2023-09-23
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20790 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦52Â÷ ÀÎõºÎõÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-15 0 10 2024-05-27
20789 ¼­¿ï 2024³â ´ëÇѽŰæ±ÙÀ°ÁúȯÇÐȸ ¿¬¼ö°­Á : 2024-06-15 0 7 2024-05-27
20788 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-15 0 10 2024-05-27
20787 Ãæ³² (¿Â¶óÀÎ)2024³âµµ Ãæû³²µµÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 8 2024-05-27
20786 ºÎ»ê KSMO ºÎ»ê¿ï»ê°æ³²/´ë±¸°æºÏÁöȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2024-06-14 0 7 2024-05-27
20785 ¼­¿ï 2024³â ´ëÇѺҾÈÀÇÇÐȸ Ãá°èÇмú´ëȸ (´Ù½Ã, °Ü¿ï³ª¹«¿¡¼­ º½ ³ª¹«¿¡·Î From Traditional approaches to Innovation in Psychiatry) : 2024-06-14 0 7 2024-05-27
20784 ¼­¿ï ´ëÇÑ°áÇÙÇùȸ 2024³â °áÇÙ°ü¸®±³À° 1±â(2ÀÏÂ÷) : 2024-06-14 0 5 2024-05-27
20783 ¼­¿ï Á¦14Â÷ Çѱ¹ÃÖ¼Òħ½ÀÃéÀå¼ö¼ú¿¬±¸È¸ : 2024-06-14 0 5 2024-05-27
20782 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç (2ÀÏÂ÷) : 2024-06-14 0 10 2024-05-27
20781 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø RARE DISEASE SYMPOSIUM 2024 : 2024-06-14 0 3 2024-05-27
20780 ºÎ»ê 2024 ´ëÇѽŰæ¿Ü°úÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Á¦2Â÷ Á¤±âÇмú´ëȸ : 2024-06-14 0 12 2024-05-27
20779 ¼­¿ï 2024 ´ëÇÑÀÇÇÐȸ Çмú´ëȸ : 2024-06-14 0 7 2024-05-27
20778 ¼­¿ï ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ 2024³â Á¦19Â÷ Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-14 0 9 2024-05-27
20777 ¼­¿ï 2024 ´ëÇÑÈ­»óÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-14 0 8 2024-05-27
20776 ºÎ»ê 2024³â Çѱ¹°£´ãÃé¿Ü°úÇÐȸ ºÎ¿ï°æÁöȸ °£ÀÌ½Ä ½ÉÆ÷Áö¾ö : 2024-06-14 0 7 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷